A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors.

The aim of this study was to fabricate and characterize in vitro a novel composite scaffold that, combining good mechanical properties with a controlled and sustained release of bioactive pro-angiogenetic growth factors, should be useful for angiogenesis induction in organs/tissues in which is also necessary to give resistance and mechanical strength. Composite scaffolds, constituted by a synthetic biocompatible material, a poly(ether)urethane-polydimethylsiloxane blend, and a biological polymer, the fibrin, were manufactured by spray, phase-inversion technique. During the manufacturing process heparin and heparin-binding growth factors, such as VEGF(165) and bFGF, were incorporated into the fibrin layer. Microscopical examinations showed a homogeneous fibrin layer firmly adherent on top of the synthetic material. Tensile tests highlighted the high elasticity of the composite scaffold and its capability to maintain integrity up to high deformation. VEGF(165) and bFGF release were controlled by fibrinogen concentration, whereas it was not affected by heparin concentration, as revealed by ELISA assay. The biological activity of the released growth factors was maintained as demonstrated by HUVEC proliferation. Finally, scaffolds induced a low monocyte mRNA expression of inflammatory markers (IL-8, L-SEL, LFA-1 and iNOS). In conclusion, the new composite scaffolds, once implanted, providing a co-localization and temporal distribution of bioactive VEGF and bFGF in addition to good mechanical properties, may be useful to stimulate new vessels formation in ischemic tissues.

[1]  S. Gogolewski,et al.  Nerve regeneration using tubular scaffolds from biodegradable polyurethane. , 2007, Acta neurochirurgica. Supplement.

[2]  K. Ishikawa,et al.  Basic Fibroblast Growth Factor Increases Regional Myocardial Blood Flow and Salvages Myocardium in the Infarct Border Zone in a Rabbit Model of Acute Myocardial Infarction , 1999, Angiology.

[3]  A. Condurache,et al.  VEGF165 and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo , 2007, Langenbeck's Archives of Surgery.

[4]  Enrica Briganti,et al.  PDMS content affects in vitro hemocompatibility of synthetic vascular grafts , 2007, Journal of materials science. Materials in medicine.

[5]  M. van Griensven,et al.  Sustained (rh)VEGF165 release from a sprayed fibrin biomatrix induces angiogenesis, up‐regulation of endogenous VEGF‐R2, and reduces ischemic flap necrosis , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[6]  A. Sahni,et al.  Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.

[7]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[8]  W. Schwenk,et al.  A prospective randomized trial: the influence of intraoperative application of fibrin glue after radical inguinal/iliacal lymph node dissection on postoperative morbidity. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  Small diameter polyurethane-polydimethylsiloxane vascular prostheses made by a spraying, phase-inversion process , 1992 .

[10]  P. Janmey,et al.  Fibrin gels and their clinical and bioengineering applications , 2009, Journal of The Royal Society Interface.

[11]  P. Losi,et al.  Silicone based polyurethane materials: a promising biocompatible elastomeric formulation for cardiovascular applications , 2006, Journal of materials science. Materials in medicine.

[12]  Carr Me,et al.  Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. , 1995 .

[13]  Y. Ikada,et al.  Bone regeneration by basic fibroblast growth factor complexed with biodegradable hydrogels. , 1998, Biomaterials.

[14]  J. Ware,et al.  Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. , 2002, The Journal of thoracic and cardiovascular surgery.

[15]  P. Galletti,et al.  Microporous small diameter PVDF-TrFE vascular grafts fabricated by a spray phase inversion technique. , 1992, ASAIO journal.

[16]  J. Hubbell,et al.  Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels. , 1998, Journal of biomedical materials research.

[17]  D. Rootman,et al.  Fibrin glue versus sutures for attaching the conjunctival autograft in pterygium surgery: a prospective observer masked clinical trial , 2008, British Journal of Ophthalmology.

[18]  A. Sahni,et al.  Binding of Basic Fibroblast Growth Factor to Fibrinogen and Fibrin* , 1998, The Journal of Biological Chemistry.

[19]  S. Sakiyama-Elbert,et al.  Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[20]  L. Lorand,et al.  Structural origins of fibrin clot rheology. , 1999, Biophysical journal.

[21]  C. Doillon,et al.  Heparin-fibroblast growth factor-fibrin complex: in vitro and in vivo applications to collagen-based materials. , 1994, Biomaterials.

[22]  P. Koolwijk,et al.  Role of Fibrin Matrix in Angiogenesis , 2001, Annals of the New York Academy of Sciences.

[23]  Y. Ikada,et al.  Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels , 1994 .

[24]  J. Turnbull,et al.  Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.

[25]  Byung-Soo Kim,et al.  Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[26]  R. Hendel,et al.  Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.

[27]  Byung-Soo Kim,et al.  Controlled release of nerve growth factor from fibrin gel. , 2007, Journal of biomedical materials research. Part A.

[28]  M. Klagsbrun,et al.  Purification and characterization of heparin-binding endothelial cell growth factors. , 1986, The Journal of biological chemistry.

[29]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[30]  E. Hunziker,et al.  Release kinetics of transforming growth factor-beta1 from fibrin clots. , 2003, Biotechnology and Bioengineering.

[31]  P. Galletti,et al.  In vivo evaluation of porous versus skinned polyurethane-polydimethylsiloxane small diameter vascular grafts. , 1991, ASAIO transactions.

[32]  L. Broemeling,et al.  The Safety and Effect of Topically Applied Recombinant Basic Fibroblast Growth Factor on the Healing of Chronic Pressure Sores , 1992, Annals of surgery.

[33]  Catalina Wong,et al.  Fibrin-based biomaterials to deliver human growth factors , 2003, Thrombosis and Haemostasis.

[34]  David J Mooney,et al.  Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Y. Ouchi,et al.  VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B–PDGFRβ signaling , 2005, Journal of Cell Science.

[36]  T. Nakamura,et al.  Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. , 1996, Biological & pharmaceutical bulletin.

[37]  A. Schor,et al.  Growth factors in the treatment of diabetic foot ulcers , 2003, The British journal of surgery.

[38]  K. Matsushima,et al.  Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. , 1998, Cytokine & growth factor reviews.

[39]  K. Kugiyama,et al.  Angiogenic strategy for human ischemic heart disease: Brief overview , 2004, Molecular and Cellular Biochemistry.

[40]  R. Coleman,et al.  Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. , 2004, The Annals of thoracic surgery.

[41]  D. Heimbach,et al.  Basic fibroblast growth factor in the early human burn wound. , 1994, The Journal of surgical research.

[42]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[43]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[44]  D. Moodie,et al.  Long-term follow-up of aortic coarctation in infants, children and adults , 1993, Cardiology in the Young.

[45]  J. Hubbell,et al.  Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. , 2000, Journal of controlled release : official journal of the Controlled Release Society.